drugset / Trial / NCT03154775
Study of Safety and Efficacy of C-CAR011 in B-NHL Patients
Phase 1
Unknown
15 enrolled
Shanghai AbelZeta Ltd.
Shanghai Tongji Hospital, Tongji University School of Medicine · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy of C-CAR011 therapy in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL).
Timeline
- Start
- 2017-05-03
- Primary completion
- 2018-04-30
- Completion
- 2018-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | C-CAR011 | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | C-CAR011 | Cell therapy | 5e+06 cells/kg | Intravenous |